Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lipopeptide AB
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Leg Ulcer|Diabetic Foot|Inflammation|Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2300067840 | N/A |
Recruiting |
COVID-19 |
2026-12-31 |
|
ChiCTR2200063622 | N/A |
Recruiting |
Coronavirus Infections|Pneumonia |
2022-09-30 |
|
ChiCTR2000029120 | N/A |
Not yet recruiting |
Unknown |
2021-02-01 |
|
ChiCTR2000029139 | N/A |
Not yet recruiting |
Unknown |
2021-02-01 |